Suppr超能文献

可乐定作为一种策略,用于停止危重症患者的右美托咪定镇静:叙事性综述。

Clonidine as a strategy for discontinuing dexmedetomidine sedation in critically ill patients: A narrative review.

机构信息

University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, and UCHealth Memorial Hospital, Colorado Springs, CO.

University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, and UT Health San Antonio, San Antonio, TX.

出版信息

Am J Health Syst Pharm. 2020 Mar 24;77(7):515-522. doi: 10.1093/ajhp/zxaa013.

Abstract

PURPOSE

To review the efficacy and safety of transitioning from dexmedetomidine to clonidine to facilitate weaning of patients from sedation with dexmedetomidine. There is a paucity of data describing dexmedetomidine withdrawal syndrome (DWS) as well as clonidine's place in therapy for DWS. This review will describe and analyze current literature to provide clinical recommendations.

SUMMARY

A MEDLINE literature search was performed to identify original research articles describing DWS and/or transitioning from dexmedetomidine to clonidine for the purpose of weaning patients from sedation with dexmedetomidine. Four case reports describing DWS, 3 case reports describing the use of clonidine to treat DWS, and 3 observational studies describing the use of clonidine to facilitate dexmedetomidine weaning were identified. The incidence of and risk factors for DWS are unknown; factors including patient age and dexmedetomidine infusion rate, loading dose, and discontinuation strategy have inconsistent associations with DWS. All cases of DWS have been associated with infusion durations greater than 72 hours. While there are limited data describing clonidine use for the treatment of dexmedetomidine withdrawal, clonidine appears to be beneficial for dexmedetomidine weaning and its use for that purpose has been well described. Clonidine dosages that have been assessed for discontinuing dexmedetomidine vary from 0.1 to 0.3 mg orally or enterally every 6 to 8 hours; one study assessed use of transdermal clonidine (100 µg/24 h patch). Patients with extensive cardiac comorbidities may be more susceptible to adverse effects of clonidine, which may limit the drug's use for DWS intervention.

CONCLUSION

Despite limited supportive data, clonidine provides a promising option for sedation management in adult ICU patients, with successful transitions from dexmedetomidine reported within 24 hours after clonidine initiation.

摘要

目的

回顾从右美托咪定转为可乐定以促进右美托咪定镇静患者撤机的疗效和安全性。目前描述右美托咪定撤药综合征(DWS)以及可乐定在 DWS 治疗中的作用的数据很少。本综述将描述和分析当前文献,以提供临床建议。

摘要

进行了 MEDLINE 文献检索,以确定描述 DWS 和/或从右美托咪定转为可乐定以促进右美托咪定镇静患者撤机的原始研究文章。确定了 4 篇描述 DWS 的病例报告,3 篇描述使用可乐定治疗 DWS 的病例报告,以及 3 篇描述使用可乐定促进右美托咪定撤机的观察性研究。DWS 的发生率和危险因素尚不清楚;包括患者年龄和右美托咪定输注率、负荷剂量和停药策略在内的因素与 DWS 之间的关联不一致。所有 DWS 病例均与输注时间超过 72 小时有关。虽然描述可乐定用于治疗右美托咪定撤药的资料有限,但可乐定似乎对右美托咪定撤机有益,并且已很好地描述了其用于该目的的用途。评估用于停止右美托咪定的可乐定剂量为口服或肠内每 6 至 8 小时 0.1 至 0.3 毫克;一项研究评估了使用透皮可乐定(100μg/24h 贴片)。患有广泛心脏合并症的患者可能更容易受到可乐定的不良反应影响,这可能限制了该药物在 DWS 干预中的使用。

结论

尽管支持性数据有限,但可乐定为成人 ICU 患者的镇静管理提供了一种有前途的选择,在开始使用可乐定后 24 小时内成功完成了从右美托咪定的转换。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验